Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{48d0571832b646298c2fdf8fe5123e75,
title = "Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study",
abstract = "BACKGROUND: Gender differences in symptomatology in chronic schizophrenia and first episode psychosis patients have often been reported. However, little is known about gender differences in those at risk of psychotic disorders. This study investigated gender differences in symptomatology, drug use, comorbidity (i.e. substance use, affective and anxiety disorders) and global functioning in patients with an at-risk mental state (ARMS) for psychosis.METHODS: The sample consisted of 336 ARMS patients (159 women) from the prodromal work package of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI; 11 centers). Clinical symptoms, drug use, comorbidity and functioning were assessed at first presentation to an early detection center using structured interviews.RESULTS: In unadjusted analyses, men were found to have significantly higher rates of negative symptoms and current cannabis use while women showed higher rates of general psychopathology and more often displayed comorbid affective and anxiety disorders. No gender differences were found for global functioning. The results generally did not change when corrected for possible cofounders (e.g. cannabis use). However, most differences did not withstand correction for multiple testing.CONCLUSIONS: Findings indicate that gender differences in symptomatology and comorbidity in ARMS are similar to those seen in overt psychosis and in healthy controls. However, observed differences are small and would only be reliably detected in studies with high statistical power. Moreover, such small effects would likely not be clinically meaningful.",
keywords = "Comorbidity, Functioning, Gender differences, Risk for psychosis, Sex differences",
author = "Stephanie Menghini-M{\"u}ller and Erich Studerus and Sarah Ittig and Ulrike Heitz and Laura Egloff and Christina Andreou and Valmaggia, {Lucia R} and Kempton, {Matthew J} and {van der Gaag}, Mark and {de Haan}, Lieuwe and Barnaby Nelson and Neus Barrantes-Vidal and Merete Nordentoft and Stephan Ruhrmann and Gabriele Sachs and Rutten, {Bart P} and Os, {Jim van} and Anita Riecher-R{\"o}ssler and Philip McGuire and Valmaggia, {Lucia R} and Kempton, {Matthew J} and Maria Calem and Stefania Tognin and Gemma Modinos and {de Haan}, Lieuwe and {van der Gaag}, Mark and Eva Velthorst and Kraan, {Tamar C} and {van Dam}, {Daniella S} and Nadine Burger and Barnaby Nelson and Patrick McGorry and Amminger, {G Paul} and Christos Pantelis and Athena Politis and Joanne Goodall and Anita Riecher-R{\"o}ssler and Stefan Borgwardt and Charlotte Rapp and Sarah Ittig and Erich Studerus and Renata Smieskova and Rodrigo Bressan and Ary Gadelha and Dorte Nordholm and Lasse Randers and Kristine Krakauer and Louise Glenth{\o}j and Birte Glenth{\o}j and Merete Nordentoft and {EU-GEI High Risk Study Group}",
note = "Copyright {\circledC} 2019. Published by Elsevier Masson SAS.",
year = "2019",
month = "6",
doi = "10.1016/j.eurpsy.2019.04.007",
language = "English",
volume = "59",
pages = "52--59",
journal = "European Psychiatry",
issn = "0924-9338",
publisher = "Elsevier France Editions Scientifiques et Medicales",

}

RIS

TY - JOUR

T1 - Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning - Results from the EU-GEI study

AU - Menghini-Müller, Stephanie

AU - Studerus, Erich

AU - Ittig, Sarah

AU - Heitz, Ulrike

AU - Egloff, Laura

AU - Andreou, Christina

AU - Valmaggia, Lucia R

AU - Kempton, Matthew J

AU - van der Gaag, Mark

AU - de Haan, Lieuwe

AU - Nelson, Barnaby

AU - Barrantes-Vidal, Neus

AU - Nordentoft, Merete

AU - Ruhrmann, Stephan

AU - Sachs, Gabriele

AU - Rutten, Bart P

AU - Os, Jim van

AU - Riecher-Rössler, Anita

AU - McGuire, Philip

AU - Valmaggia, Lucia R

AU - Kempton, Matthew J

AU - Calem, Maria

AU - Tognin, Stefania

AU - Modinos, Gemma

AU - de Haan, Lieuwe

AU - van der Gaag, Mark

AU - Velthorst, Eva

AU - Kraan, Tamar C

AU - van Dam, Daniella S

AU - Burger, Nadine

AU - Nelson, Barnaby

AU - McGorry, Patrick

AU - Amminger, G Paul

AU - Pantelis, Christos

AU - Politis, Athena

AU - Goodall, Joanne

AU - Riecher-Rössler, Anita

AU - Borgwardt, Stefan

AU - Rapp, Charlotte

AU - Ittig, Sarah

AU - Studerus, Erich

AU - Smieskova, Renata

AU - Bressan, Rodrigo

AU - Gadelha, Ary

AU - Nordholm, Dorte

AU - Randers, Lasse

AU - Krakauer, Kristine

AU - Glenthøj, Louise

AU - Glenthøj, Birte

AU - Nordentoft, Merete

AU - EU-GEI High Risk Study Group

N1 - Copyright © 2019. Published by Elsevier Masson SAS.

PY - 2019/6

Y1 - 2019/6

N2 - BACKGROUND: Gender differences in symptomatology in chronic schizophrenia and first episode psychosis patients have often been reported. However, little is known about gender differences in those at risk of psychotic disorders. This study investigated gender differences in symptomatology, drug use, comorbidity (i.e. substance use, affective and anxiety disorders) and global functioning in patients with an at-risk mental state (ARMS) for psychosis.METHODS: The sample consisted of 336 ARMS patients (159 women) from the prodromal work package of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI; 11 centers). Clinical symptoms, drug use, comorbidity and functioning were assessed at first presentation to an early detection center using structured interviews.RESULTS: In unadjusted analyses, men were found to have significantly higher rates of negative symptoms and current cannabis use while women showed higher rates of general psychopathology and more often displayed comorbid affective and anxiety disorders. No gender differences were found for global functioning. The results generally did not change when corrected for possible cofounders (e.g. cannabis use). However, most differences did not withstand correction for multiple testing.CONCLUSIONS: Findings indicate that gender differences in symptomatology and comorbidity in ARMS are similar to those seen in overt psychosis and in healthy controls. However, observed differences are small and would only be reliably detected in studies with high statistical power. Moreover, such small effects would likely not be clinically meaningful.

AB - BACKGROUND: Gender differences in symptomatology in chronic schizophrenia and first episode psychosis patients have often been reported. However, little is known about gender differences in those at risk of psychotic disorders. This study investigated gender differences in symptomatology, drug use, comorbidity (i.e. substance use, affective and anxiety disorders) and global functioning in patients with an at-risk mental state (ARMS) for psychosis.METHODS: The sample consisted of 336 ARMS patients (159 women) from the prodromal work package of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI; 11 centers). Clinical symptoms, drug use, comorbidity and functioning were assessed at first presentation to an early detection center using structured interviews.RESULTS: In unadjusted analyses, men were found to have significantly higher rates of negative symptoms and current cannabis use while women showed higher rates of general psychopathology and more often displayed comorbid affective and anxiety disorders. No gender differences were found for global functioning. The results generally did not change when corrected for possible cofounders (e.g. cannabis use). However, most differences did not withstand correction for multiple testing.CONCLUSIONS: Findings indicate that gender differences in symptomatology and comorbidity in ARMS are similar to those seen in overt psychosis and in healthy controls. However, observed differences are small and would only be reliably detected in studies with high statistical power. Moreover, such small effects would likely not be clinically meaningful.

KW - Comorbidity

KW - Functioning

KW - Gender differences

KW - Risk for psychosis

KW - Sex differences

UR - http://www.scopus.com/inward/record.url?scp=85065137693&partnerID=8YFLogxK

U2 - 10.1016/j.eurpsy.2019.04.007

DO - 10.1016/j.eurpsy.2019.04.007

M3 - Journal article

VL - 59

SP - 52

EP - 59

JO - European Psychiatry

JF - European Psychiatry

SN - 0924-9338

ER -

ID: 58228288